News

The meta-analysis observed an enhanced plasma uric acid concentration in patients with periodontitis when compared with controls.

At month 3, patients treated with tofacitinib achieved higher rates of ACR20/50, MDA, and PASI75 in both sexes when compared with the placebo. However, female patients were less likely to achieve MDA when compared with males.

At week 24, serum IGF-1 levels increased and body weight was reduced by an average of 6.5% from baseline.

In a multivariate logistic regression analysis, the HAQ score was significantly associated with both anxiety and depression, indicating worse functional status and higher disease activity.

The collaboration, titled the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), is the first public-private partnership designed to advance lupus discoveries and highlight patient perspective in drug development.

A cross-sectional, case-controlled cohort study evaluated the cardiorespiratory and neuromuscular fitness of Finnish patients with JIA and healthy controls.

Treatment with secukinumab was safe and effective for patients with ankylosing spondylitis and psoriatic arthritis, with significant reductions in disease activity scores observed through 52 weeks.

The guidelines were created using a panel of rheumatologists, orthopedic surgeons, and patients.

New meta-analysis show patient demographics—as well as their pre-existing comorbidities and COVID-19 vaccination status—may significantly define their risk of long-term conditions.

Compared with other bDMARDs, patients with rheumatoid arthritis treated with tofacitinib had a 4-fold reduced incidence of interstitial lung disease.

A retrospective analysis comparing propensity score matched metformin users against sulfonylurea users, results of the study indicate metformin use was associated with a 24% reduction in relative risk of developing osteoarthritis.

Upadacitinib, a selective and reversible Janus kinase (JAK) inhibitor, may be a promising treatment option for patients with systemic lupus erythematosus.

SEL-212, an alternative to standard therapy that is administered once monthly, has proven to be particularly helpful for patients with severe gout, a historically underserved population.

An analysis of perimenopausal women with rheumatoid arthritis indicated that patients receiving exogenous sex hormones more frequently achieved SDAI- and CDAI-defined remission.

The systematic review summarized the impact of biologics targeting the IL-23/Th17 axis.

An announcement from Selecta Biosciences and Sobi provide the latest update on DISSOLVE clinical program, with new data indicating SEL-212 met the primary endpoint of achieving serum urate control during month 6.

Often overlooked and underfunded, as well as being underpaid compared to internal medicine, it is difficult to convince prospective medical students, many of whom already have substantial debt, to choose a career in pediatric rheumatology.

The phase 3 DISCOVER-1 and DISCOVER-2 studies were used to evaluate dactylitis resolution in guselkumab-treated patients with psoriatic arthritis through 1 year.

Polypharmacy, defined as ≥5 concomitant drugs, was significantly higher in patients with psoriatic arthritis when compared with controls (49% vs 17%, respectively).

Adult patients with traumatic brain injury-induced fibromyalgia were randomized 1:1 to receive hyperbaric oxygen therapy or pharmacological intervention.

Results demonstrate that guselkumab was well-tolerated in studies continuing for 1 to 2 years among patients with active psoriatic arthritis regardless of TNFi experience.

Higher baseline Disease Activity Index for Psoriatic Arthritis (DAPSA) was associated with reduced probability of achieving low disease activity or remission.

Results of a recent study showed that the risk of pneumocystis jiroveci pneumonia (PJP) is low in patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), therefore discouraging the routine prescribing of PJP prophylaxis for this patient population.

New pooled data from DISCOVER-1 and DISCOVER-2 show the injection biologic provided full resolution of dactylitis in three-fourths of patients by week 52.

Dialysis-dependent patients in the US with gout have an increased risk of cardiovascular comorbidities, hospitalization, and mortality. Results emphasize the need for improved treatments to enhance outcomes for this patient population.

A cohort analysis from Norway suggests women with active psoriatic arthritis or axial spondylitis are at greater risk of either elective or emergency delivery procedures.

An international pilot study shows a probiotic candidate may improve both management of gout and relevant blood serum levels in treated patients.

New cohort analysis data show women with fibromyalgia are at an increased risk of depression—which is also correlated with a worse life expectancy over 8 years.

Disease activity and burden were higher in patients with rheumatoid arthritis with Medicaid or Medicare coverage, African American patients, and those residing in Southern regions.

A brief increase in venous thromboembolism (VTE) was reported within 30 days after a hospitalization or primary care visit for gout flare. The highest incidence occurred during the 16-30 day period after the flare.